Navigation Links
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
Date:4/6/2009

y sleepy as narcoleptics and that the treatment effect for those on NUVIGIL was the largest we have seen to date. We are pleased that this positive study will allow us to file our first sNDA for an acute use of NUVIGIL."

NUVIGIL was generally well-tolerated in the study. The adverse events reported in this study of acute use are consistent with chronic use in the current NUVIGIL label. The most common adverse events in the study, observed more frequently with NUVIGIL use, included headache, anxiety, nausea, palpitations and fatigue.

Jet lag disorder is an acute circadian rhythm sleep disorder that results from rapid travel across several time zones. This disorder affects approximately 70 million American travelers annually and gradually resolves once a person adjusts to the new local time.

Circadian rhythm sleep disorders are disruptions in a person's internal body clock, which controls sleep patterns. When the internal body clock is disrupted, certain symptoms may develop affecting a person's ability to sleep, stay awake and function normally. Circadian rhythm sleep disorders can be caused by many factors, including shift work, time zone changes and medications.

Cephalon is preparing to launch NUVIGIL, the longer-lasting isomer of modafinil, in the third quarter of 2009. NUVIGIL is not approved for the treatment of jet lag disorder or its associated symptoms. The U.S. Food and Drug Administration-approved prescribing information for NUVIGIL, including bolded warnings, is available at www.NUVIGIL.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
2. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
3. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
4. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
5. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
8. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
9. Schering-Plough Announces Results of the Early ACS Trial
10. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
11. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... -- Edwards Lifesciences Corporation (NYSE: EW ), the global ... monitoring, today reported net income for the quarter ended ... share.  Net income for the same period a year ... and non-GAAP net income was $82.1 million, or $0.76 ... quarter ended March 31, 2015 increased 13.0 percent to $590.3 ...
(Date:4/23/2015)... DUBLIN , April 23, 2015  Jazz Pharmaceuticals ... will report its 2015 first quarter financial results on ... financial markets.  Company management will host a live audio ... p.m. IST to discuss first quarter 2015 financial results ... Interested parties may access the live audio webcast via ...
(Date:4/23/2015)... , April 23, 2015  DanDrit Biotech A/S ... USA , Inc. ("DanDrit"), (symbol : ... approved vaccine for the treatment of colorectal cancer, ... Pharma have signed a partnership agreement in ... collaboration agreement advances DanDrit,s goal to deliver an ...
Breaking Medicine Technology:Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2DanDrit Biotech and Riyadh Pharma Sign Partnership Agreement 2
... Corp. (Nasdaq: BSTC ; the "Company" or ... products, today announced that its Board of Directors has ... 14, 2002 and previously amended June 19, 2003 (the ... for determining "Acquiring Person" status under the Rights Agreement ...
... Feb. 7, 2011 Cancer ... served by just 11 modern radiotherapy linear accelerators, now ... Systems (NYSE: VAR). Treatments using fast and efficient RapidArc® ... Clinac® iX medical linear accelerator at the new United ...
Cached Medicine Technology:Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems 2Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems 3
(Date:4/25/2015)... Sports controversies continue to revolve around issues of ... the case with the Miami Dolphins and Richie Incognito, or off ... Ray Rice domestic abuse case. In a recent episode of ... the implications of locker room culture on teams. He examines what ... should do to improve the locker room as a work place. ...
(Date:4/24/2015)... 24, 2015 Multi Customer Discount , ... pumping ( http://www.zeitersseptics.com/multi-customer-discount.html ) of 1000-1500 gallons in Zeiter's ... program. This does not include any Dig fees, or ... per person. If someone is part of this group ... totaling approximately 2500 gallons or more, the cost would ...
(Date:4/24/2015)... April 24, 2015 Lipitor lawsuits ... in the federal multidistrict litigation underway in U.S. ... court documents, the parties involved in the proceeding ... detailing, among other things, preparation for the litigation’s ... for both plaintiffs and defendants have conducted depositions ...
(Date:4/24/2015)... 2015 Carinsurancequotesinfo.com has released a new ... how to qualify for auto insurance as ... for auto insurance online, without having to follow a ... single parents can reduce their auto insurance expenses. The ... properly explained. , Clients can now visit an ...
(Date:4/24/2015)... With years of experience providing ... proud to be partnered with a veterinary college where ... year. This partnership has brought new payment options for ... After providing an in-house payment plan for many years, ... wanted to increase financing options available to avoid having ...
Breaking Medicine News(10 mins):Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 3Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2
... are calling for greater clarity on the legal implications of ... that this is often done following staff needlestick injuries, in ... the September issue of Anaesthesia , reports on the ... England, Wales and Northern Ireland. It is accompanied by ...
... rapidly, the University of Missouri has made a commitment to ... community and across the country. MU was one of ... Difficult Dialogues Initiative (DDI) in 2005, and one of only ... additional $100,000 grant in 2008. DDI activities focus on teaching ...
... , MONDAY, Aug. 30 (HealthDay News) -- The rate of ... steps are needed to reverse the trend, a new study ... delivery climbed by more than 50 percent, and "one in ... lead researcher Dr. Jun Zhang, of the Eunice Kennedy Shriver ...
... with acute coronary syndromes initially treated with the anticoagulant ... angioplasty) and received a lower dose of the anticoagulant ... rate of major bleeding and vascular access site complications, ... September 22 issue of JAMA . The study ...
... University, has found that lower doses of a ... did not reduce bleeding or vascular complications compared ... with a blood thinner, fondaparinux. In a ... McMaster University showed that a blood thinner fondaparinux ...
... -- The incidence of acute myocardial infarction in Italy ... 2001 and 2005, according to a comprehensive study funded ... charity for biomedical research and health education in Spoleto, ... Experimental Research . "The study suggests that more information ...
Cached Medicine News:Health News:Hospitals face legal dilemma if they test incapacitated patients after needle accidents 2Health News:Hospitals face legal dilemma if they test incapacitated patients after needle accidents 3Health News:Hospitals face legal dilemma if they test incapacitated patients after needle accidents 4Health News:Difficult Dialogues Initiative promotes diversity at MU, around country 2Health News:Almost 1 in 3 First-Time Deliveries Now Via C-Section 2Health News:Almost 1 in 3 First-Time Deliveries Now Via C-Section 3Health News:Almost 1 in 3 First-Time Deliveries Now Via C-Section 4Health News:Lower-dose heparin use during coronary procedure does not appear to reduce risk of major bleeding 2Health News:Lower-dose heparin use during coronary procedure does not appear to reduce risk of major bleeding 3Health News:Drug trial results refine treatment during angioplasty operations 2Health News:Drug trial results refine treatment during angioplasty operations 3Health News:Heart attacks jump in young Italian women 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: